S&P 500 struggles for direction as investor await inflation data
Genprex, Inc. (NASDAQ:GNPX) announced Tuesday that it has regained compliance with the Nasdaq Capital Market’s minimum bid price requirement, following a determination by the Nasdaq Hearings Panel. The company also received an extension until December 31, 2025, to demonstrate compliance with the minimum stockholders’ equity requirement for continued listing.
According to a statement based on a recent SEC filing, the Nasdaq Hearings Panel had previously granted Genprex an exception through October 31, 2025, to meet both the $1.00 minimum bid price and the minimum stockholders’ equity requirements. On November 25, the Panel notified Genprex that it had met the bid price requirement. The company now has until the end of the year to address the equity requirement.
The Panel retains the discretion to grant Genprex continued listing through February 9, 2026, if requested. Under the terms of the extension, Genprex is required to promptly notify the Panel of any significant events that could affect its ability to meet the requirements. The Panel may reconsider the extension if circumstances arise that it considers make continued listing inadvisable.
Genprex stated in the filing that it anticipates the need for additional capital raising transactions to achieve compliance with the stockholders’ equity requirement. The company noted there is no guarantee that financing will be available on acceptable terms.
Genprex’s common stock continues to trade on the Nasdaq Capital Market under the symbol GNPX. This information is based on a press release statement contained in the company’s Form 8-K filing with the Securities and Exchange Commission.
In other recent news, Genprex, Inc. has been actively advancing its gene therapy initiatives. The company reported data from its Acclaim-1 Phase 1 clinical trial, which evaluated Reqorsa Gene Therapy in combination with Tagrisso for advanced non-small cell lung cancer. The study established a recommended Phase 2 dose with no dose-limiting toxicities observed. Additionally, Genprex filed a prospectus supplement with the Securities and Exchange Commission for an at-the-market offering, aiming to raise up to $75 million through the sale of additional shares. The company has already sold shares for gross proceeds of approximately $14.8 million under this agreement.
In terms of intellectual property, Genprex received a U.S. patent for its Reqorsa Gene Therapy in combination with PD-L1 antibodies for cancer treatment, extending protection through 2037. Furthermore, the European Patent Office intends to grant a patent for the same therapy used with PD-1 antibodies, expanding Genprex’s global patent portfolio. Lastly, Genprex announced a registered direct offering and concurrent private placement to raise about $3.4 million, selling shares at $9.00 per share and issuing warrants for additional shares. These developments highlight Genprex’s ongoing efforts to secure funding and strengthen its therapeutic offerings in the cancer treatment landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.